Skip to search formSkip to main contentSkip to account menu

CVT-E002

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Objectives  There is interest in developing new compounds to enhance the immune response to airway virus infections. CVT‐E002 is… 
2011
2011
CVT-E002 (a proprietary extract) was found to be effective in the prevention of upper respiratory infections (URIs) in healthy… 
2011
2011
In a recent study involving normal, juvenile mice, we showed that CVT-E002, a proprietary extract (Afexa Life Sciences, Inc.) of… 
2009
2009
The present study evaluated the dose-related effects of CVT-E002, a proprietary extract of Panax quinquefolius (CV Technologies… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND COLD-fX (CVT-E002), a proprietary extract of the roots of North American ginseng (Panax quinquefolium), rich in poly… 
2006
2006
In a previous study, COLD-fX (CVT-E002), a proprietary extract of the root of North American ginseng (Panax quinuefolium), was… 
Highly Cited
2004
Highly Cited
2004
Objectives: To compare a proprietary extract of American ginseng, CVT‐E002, with placebo in preventing acute respiratory illness… 
Highly Cited
2001
Highly Cited
2001
The activity of CVT‐E002, an aqueous extract containing mainly oligosaccharides and polysaccharides from North American ginseng…